Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

the Phenotypic and Genetic Profile of Patients With Early Onset Schizophrenia Associated With Autism Spectrum Disorder. (GenAuDiss)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02565524
Recruitment Status : Recruiting
First Posted : October 1, 2015
Last Update Posted : March 29, 2018
Sponsor:
Information provided by (Responsible Party):
Fondation Lenval

Brief Summary:

Early onset schizophrenia "early dissociative disorder" is a rare disorder with a low incidence of approximately (1/5000 to 1/20000). Its link with autism spectrum disorders remains unknown although both are serious neurodevelopmental diseases. As part of the 2011-2013 Interregional hospital Clinical Research program, University Department of Child and Adolescent Psychiatry Pediatric Hospitals of CHU de Nice Lenval identified patients with a complex phenotype characterized by an early schizophrenia associated with autism spectrum disorders and developmental disabilities in mild to moderate. This phenotype could be a new syndrome.

The goal of our project is to define the genetic causes of this phenotype. The technique of high throughput sequencing will be used to obtain the sequence of exomes of these patients and their families. This study will therefore be important to give an accurate diagnosis for patients and their families. Moreover, we believe that this project will identify new genes involved allowing a better understanding of the pathophysiology. Recent studies show the involvement of mutations in several genes (eg NRXN1 and UPF3B) in these different clinical phenotypes. However, the genetic basis of the childhood and early onset schizophrenia are much less well known than those of autism spectrum disorder


Condition or disease Intervention/treatment Phase
Schizophrenia Dissociative Disorders Other: genetic and phenotypic profile Not Applicable

Detailed Description:

Introduction: Early-onset Schizophrenia (EOS) is a rare and severe condition displaying early dissociative disorder (i.e., age of onset < 18 years). A higher rate of neurodevelopmental abnormalities is observed in EOS compared to adult onset schizophrenia (AOS). Thus, patients affected by EOS typically present intellectual, learning, communication or neuromotor impairments, as well as attention deficit hyperactivity disorder. Early signs of autism spectrum disorders (ASD) are also found in 30% of patients with EOS.

Cytogenetics abnormalities, including copy number variations (CNVs), are frequent in neurodevelopmental disorders and have been linked to ASD physiopathology. Implicated genes encode proteins playing a role in brain development, synaptic morphology, plasticity and neurogenesis. In addition, an increasing number of genetic abnormalities are shared by EOS and ASD, suggesting that schizophrenia can be considered a neurodevelopmental disorder.

The main objective of the present study is to identify mutations in genes involved in neurodevelopmental pathways in our cohort of patients affected by both EOS and ASD.

Method and analysis: We describe here a multicenter study in a pediatric population named "Exploration and characterization of genetic and phenotypic profile of the 'early dissociative disorder' associated with autism spectrum disorder (GenAuDiss)". The study started in April 2014. The inclusion criteria are: age 7 to 22 years, diagnoses of EOS with co-morbid ASD and IQ > 50; as well as parents and siblings of the included patients.

We perform standardized psychiatric assessments (MINI, K-SADS-PL, PANSS, SANS, TCI 226, and AQ) and neurocognitive evaluations (IQ, TMT A/B, and verbal fluency). Then, we study variants of the coding part of the DNA (exome), using next generation sequencing (NGS) process on trio (mother, father, and child). Divers bio-informatics tools such as RVIS and PolyPhen-2 will be used to prioritize the potential candidate genes. The inclusion period of this study will end in November 2019.

Ethics and dissemination: The study protocol was approved by the Ethics Committee 'Sud Méditerrané V' (number 14.002) and by the French National Agency for Medicines and Health Products Safety (ANSM 2013-A01699-36). All patients, their parents and siblings signed informed consent upon enrolment in the study.

Results of the present study should help to unravel the molecular pathology of EOS, paving the way for an early therapeutic intervention


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Exploration and Characterization of the Phenotypic and Genetic Profile of Patients With Early Onset Schizophrenia Associated With Autism Spectrum Disorder and Their First-degree Relatives (GenAuDiss).
Actual Study Start Date : May 18, 2014
Estimated Primary Completion Date : November 18, 2019
Estimated Study Completion Date : May 18, 2020


Arm Intervention/treatment
Experimental: genetic and phenotypic profile
blood sample, clinical and neurocognitive assessment
Other: genetic and phenotypic profile
Genetic and phenotypic profile, clinical and neurocognitive assessment for child with Schizophrenia and autism, their parents and brotherhood




Primary Outcome Measures :
  1. characterization of the genetic abnormalities associated to Early Onset Schizophrenia phenotypes by performing standard karyotype [ Time Frame: inclusion visit ]

    A standard karyotype at a resolution of 300 to 400 bands per haploid lot. It can diagnose numerical anomalies and certain structural abnormalities such as reciprocal translocations, inversions, deletions.

    A standard karyotype at a resolution of 300 to 400 bands per haploid lot is established initially. It can diagnose numerical anomalies and certain structural abnormalities such as reciprocal translocations, inversions, deletions Big.

    The pathological nature of these mutations will be stutied on the gene function and reaches its pattern of expression.


  2. characterization of the genetic abnormalities associated to Early Onset Schizophrenia phenotypes by performing search CGG [ Time Frame: inclusion visit ]
    A search of the CGG expansion hypermethylated in the 5 'UTR of the FMR1 gene mutation that causes Fragile X syndrome.

  3. characterization of the genetic abnormalities associated to Early Onset Schizophrenia phenotypes by performing whole exome sequencing [ Time Frame: inclusion visit ]
    Whole Exome Sequencing on trio (mother, father and child); This technology has demonstrated its power in recent years to determine the genetic causes of many rare diseases (Ropers, HH., 2012).


Secondary Outcome Measures :
  1. Intensity of positive symptoms of schizophrenia [ Time Frame: inclusion visit ]
    Evaluation of the intensity of positive and negative symptoms, general psychopathology and subtypes of schizophrenia by using positive and negative syndrome scale (PANSS)

  2. Co-morbid psychiatric diagnosis [ Time Frame: inclusion visit ]
    Evaluation of clinical profile: by using K-SADS-PL scale for DSM IV-TR / DSM-5 co-morbid psychiatric diagnosis of patients and minor siblings and by using MINI assessments for DSM IV-TR / DSM 5 psychiatric diagnosis of parents and major siblings.

  3. Evaluation of executive and attentional by the verbal fluency test [ Time Frame: inclusion visit ]
    Evaluation of executive and attentional functions of patients using Trail Making Test (TMT) A and B and verbal fluency;

  4. Clinical evaluation of autistic symptoms [ Time Frame: inclusion visit ]
    Clinical evaluation of autistic symptoms by using AQ (Baron-Cohen) in siblings and parents

  5. Neurocognitive profile [ Time Frame: inclusion visit ]
    Evaluation of cognitive functioning by Wechsler Intelligence Scale for Children Scale IV (WISC IV).full version in patient and WISC IV abridged version in minor siblings; Wechsler Adult Intelligence Scale-III (WAIS III) in a short form in adult siblings and parents

  6. Personality dimensional test [ Time Frame: inclusion visit ]
    Personality dimensional test using computerized version of TCI 226 (Cloninger) in parents



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   7 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Of the child:

  • ≥ 7 years, <18 (below 7 years the diagnosis of schizophrenia is not possible)
  • Schizophrenia Diagnosis done using the diagnostic tool Kiddie sads
  • Autism Diagnosis done using the diagnostic scale Autism Diagnostic interview (ADI-R)
  • Intelligence quotient (IQ) ≥ 50 at Wechsler Intelligence Scale for Children (WISC) IV abridged version
  • Clinical examination
  • Affiliation to social security
  • Obtaining the authorization of the holders of parental authority

Brothers and sisters:

  • Minor or Major
  • Similarly biological parents
  • Clinical examination
  • Affiliation to social security
  • Obtaining the authorization of the holders of parental authority for minors or informed consent for major

Parents:

  • Biological Parent
  • Clinical examination
  • Affiliation to social security
  • Informed Consent

Exclusion Criteria:

Of the child:

  • Children refusing to participate
  • Children without verbal language

Brothers and sisters:

  • Children refusing to participate
  • Adults protected by law

Parents:

  • Refusing to participate
  • Adults are protected by law

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02565524


Contacts
Layout table for location contacts
Contact: Emmanuelle DOR, MD +33(0)4 92 03 03 72 dor.nedonsel@lenval.com
Contact: Olivier BAILET, PhD +33(0)4 92 03 43 94 bailet.o2@chu-nice.fr

Locations
Layout table for location information
France
Fondation Lenval Recruiting
Nice, France, 06200
Contact: Emmanuelle DOR, MD    +33(0)4 92 03 03 72    dor.nedonsel@lenval.com   
Contact: Olivier BAILET, PhD    +33(0)4 92 03 43 94    bailet.o2@chu-nice.fr   
Principal Investigator: Emmanuelle DOR, MD         
Sponsors and Collaborators
Fondation Lenval
Investigators
Layout table for investigator information
Principal Investigator: Emmanuelle DOR, MD Fondation Lenval

Layout table for additonal information
Responsible Party: Fondation Lenval
ClinicalTrials.gov Identifier: NCT02565524     History of Changes
Other Study ID Numbers: 14-HPNCL08
First Posted: October 1, 2015    Key Record Dates
Last Update Posted: March 29, 2018
Last Verified: March 2018

Keywords provided by Fondation Lenval:
schizophrenia
early dissociative disorder
genetic

Additional relevant MeSH terms:
Layout table for MeSH terms
Disease
Schizophrenia
Autism Spectrum Disorder
Dissociative Disorders
Conversion Disorder
Pathologic Processes
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Child Development Disorders, Pervasive
Neurodevelopmental Disorders
Somatoform Disorders